

---

# Will Anyone Crack the Obesity Drug Market?

*February 2011*

---



*World Leaders in Health Industry Analysis*



## **Will Anyone Crack the Obesity Drug Market?**

Published: February 2011

ISBN: 978-1-85822-414-5

© Copyright 2011 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

# Contents

<b>FOREWORD .....</b>	<b>1</b>
<b>EXECUTIVE SUMMARY .....</b>	<b>3</b>
<b>MARKET ANALYSIS .....</b>	<b>5</b>
CURRENT MARKET.....	6
<i>Sibutramine</i> .....	6
<i>Rimonabant</i> .....	7
<i>Orlistat</i> .....	7
FUTURE MARKET.....	8
Research and Development.....	8
Endogenous Hormones .....	8
Monoamine Neurotransmission Modulation .....	9
Neuropeptide Signalling Modulators.....	10
Peripheral Modulators of Metabolism .....	10
Regulation of Fat Metabolism and Food Intake: a Novel Approach? .....	11
BACKGROUND INFORMATION.....	13
What is Obesity? .....	13
What Causes Obesity.....	13
Obesity Health Risks.....	14
Controlling Energy Balance .....	15
Achieving Weight Loss .....	16
Lifestyle Modifications.....	17
Behaviour Therapy .....	17
Pharmacotherapy .....	17
Surgery .....	18
Why are New Treatments Needed?.....	19
The Prevalence of Obesity.....	19
Childhood Obesity.....	21
<b>PRODUCT ANALYSIS.....</b>	<b>22</b>
ESTABLISHED PRODUCT.....	22
Orlistat .....	22
Mode of Action .....	22
Current Status.....	22
<i>Approvals/Filings</i> .....	23
<i>Development</i> .....	23
Proof of Concept/Clinical Data.....	23
Development Risks.....	24
Company Expertise .....	25
Competition within the Market-place.....	25

## WILL ANYONE CRACK THE OBESITY DRUG MARKET?

---

Competitor Ratio Analysis.....	25
Clinical Trial Results.....	26
<i>Low-dose Orlistat</i> .....	26
<i>Xenical in Adolescents</i> .....	26
<i>Diabetes Prevention in Obese Subjects</i> .....	27
RECENTLY WITHDRAWN PRODUCT.....	28
Sibutramine.....	28
Mode of Action.....	28
Current Status.....	28
Proof of Concept/Clinical Data.....	29
Development Risks.....	29
Company Expertise.....	29
Clinical Trial Results.....	29
FILED PRODUCTS.....	32
Bupropion+naltrexone.....	32
Mode of Action.....	32
Current Status.....	32
Proof of Concept/Clinical Data.....	33
Development Risks.....	33
Company Expertise.....	34
Competition within the Market-place.....	34
<b>Patents</b> .....	34
<i>Patent Expiry</i> .....	35
Competitor Ratio Analysis.....	35
Clinical Trial Results.....	35
<i>Contrave Obesity Research (COR)</i> .....	35
Lorcaserin.....	39
Mode of Action.....	39
Current Status.....	39
Proof of Concept/Clinical Data.....	40
Development Risks.....	40
Company Expertise.....	41
Competition within the Market-place.....	41
<b>Patents</b> .....	41
<i>Patent Expiry</i> .....	41
Competitor Ratio Analysis.....	42
Clinical Trial Results.....	42
<i>BLOSSOM</i> .....	42
<i>BLOOM</i> .....	44
<i>BLOOM-DM</i> .....	46
<i>Abuse Potential</i> .....	47

Phentermine+topiramate .....	48
Mode of Action .....	48
Current Status.....	48
Proof of Concept/Clinical Data.....	49
Development Risks.....	49
Company Expertise .....	50
Competition within the Market-place.....	50
<b>Patents</b> .....	50
<i>Patent Expiry</i> .....	51
Competitor Ratio Analysis.....	51
Clinical Trial Results.....	51
<i>Long-Term Data Show Significant and Sustained Weight Loss Over Two Years</i> .....	51
<i>EQUIP (OB-302) and CONQUER (OB-303) Obesity Studies</i> .....	52
<i>EQUATE Obesity Study</i> .....	56
<i>Sleep Apnoea Phase II Study</i> .....	57
PHASE III .....	58
Cetilistat .....	58
Mode of Action .....	58
Current Status.....	58
Proof of Concept/Clinical Data.....	58
Development Risks.....	58
Company Expertise .....	59
Competition within the Market-place.....	59
Competitor Ratio Analysis.....	59
Clinical Trial Results.....	60
<i>Phase IIb</i> .....	60
Liraglutide .....	61
Mode of Action .....	61
Current Status.....	61
<i>Approvals/Filings</i> .....	61
<i>Development</i> .....	61
Proof of Concept/Clinical Data.....	61
<i>Diabetes</i> .....	61
<i>Obesity</i> .....	62
Development Risks.....	63
Company Expertise .....	63
Competition within the Market-place.....	63
<i>Data Exclusivity</i> .....	63
<i>Patent Expiry</i> .....	63
Competitor Ratio Analysis.....	64
Clinical Trial Results.....	64

## WILL ANYONE CRACK THE OBESITY DRUG MARKET?

---

<i>Type II Diabetes</i> .....	64
PHASE II.....	70
Betahistine .....	70
Mode of Action .....	70
Current Status.....	70
Proof of Concept/Clinical Data.....	71
Development Risks.....	71
Company Expertise .....	71
Competition within the Market-place.....	71
<b>Patents</b> .....	71
Competitor Ratio Analysis.....	72
Clinical Trial Results.....	72
<i>BET 209</i> .....	72
<i>Obesity</i> .....	73
Pramlintide+metreleptin .....	74
Mode of Action .....	74
Current Status.....	74
Proof of Concept/Clinical Data.....	74
Development Risks.....	74
Company Expertise .....	75
Competition within the Market-place.....	75
Competitor Ratio Analysis.....	75
Clinical Trial Results.....	75
<i>Phase II</i> .....	75
SLx-4090.....	77
Mode of Action .....	77
Current Status.....	77
Proof of Concept/Clinical Data.....	77
Development Risks.....	78
Company Expertise .....	78
Competition within the Market-place.....	78
Competitor Ratio Analysis.....	78
Clinical Trial Results.....	79
<i>Phase II - Dyslipidaemia</i> .....	79
<i>Phase I - Dyslipidaemia</i> .....	79
<i>Phase I - Safety and Tolerability</i> .....	79
Tesofensine.....	81
Mode of Action .....	81
Current Status.....	81
Proof of Concept/Clinical Data.....	81
Development Risks.....	82

Company Expertise .....	82
Competition within the Market-place.....	82
Competitor Ratio Analysis.....	83
Clinical Trial Results.....	83
<i>TIPO-5</i> .....	83
<i>TIPO-4</i> .....	83
<i>TIPO-2</i> .....	84
<i>TIPO-1</i> .....	84
<i>Cardiovascular Safety Study</i> .....	85
TM30339 .....	87
Mode of Action .....	87
Current Status.....	87
Proof of Concept/Clinical Data.....	87
Development Risks.....	88
Company Expertise .....	88
Competition within the Market-place.....	88
<b>Patents</b> .....	88
Clinical Trial Results.....	88
<i>Phase I</i> .....	88
Velneperit .....	89
Mode of Action .....	89
Current Status.....	89
Proof of Concept/Clinical Data.....	89
Development Risks.....	90
Company Expertise .....	90
Competition within the Market-place.....	90
Competitor Ratio Analysis.....	91
Clinical Trial Results.....	91
<i>Phase II</i> .....	91
Zonisamide+bupropion.....	93
Mode of Action .....	93
Current Status.....	93
Proof of Concept/Clinical Data.....	93
Development Risks.....	94
Company Expertise .....	94
Competition within the Market-place.....	94
<b>Patents</b> .....	94
Competitor Ratio Analysis.....	94
Clinical Trial Results.....	95
<i>Phase IIb</i> .....	95
<i>Post hoc analyses</i> .....	96

## WILL ANYONE CRACK THE OBESITY DRUG MARKET?

---

<i>Phase IIb results at 48 weeks</i> .....	96
<i>Phase IIb results at 24 weeks</i> .....	97
PHASE I/II.....	99
BMS-830216.....	99
Mode of Action .....	99
Current Status.....	99
Proof of Concept/Clinical Data.....	99
Obinipitide .....	100
Mode of Action .....	100
Current Status.....	100
Proof of Concept/Clinical Data.....	100
Development Risks.....	101
Company Expertise .....	101
Competition within the Market-place.....	101
<i>Patents</i> .....	101
Clinical Trial Results.....	101
<i>Phase I/II</i> .....	101
<b>METHODOLOGY</b> .....	<b>102</b>
Competitor Ratio Analysis Criteria.....	102

## List of Tables

Competitor Ratio Analysis Summary .....	6
Drugs in Clinical Development for Obesity.....	12
Relative Risks of Health Problems Associated with Obesity .....	15
The Benefits of 10kg Weight Loss .....	17

## List of Figures

Global Prevalence of Obesity, 2010.....	20
Adult Male BMI kg/m <sup>2</sup> in Selected Countries, 2010 (%) .....	20
Adult Female BMI kg/m <sup>2</sup> in Selected Countries, 2010 (%).....	21
Weight Loss Achieved With Orlistat.....	24